Source: Annual Congress 2001 - Inhaled corticosteroids
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Corren, R. B. Berkowitz, J. J. Murray, B. Prenner, K. B. Nolop (Los Angeles, Marrietta, Nashville, San Diego, Kenilworth, United States Of America). Mometasone furoate 400 μg once daily is more efficacious than budesonide 400 μg once daily in improving asthma symptoms in patients with moderate persistent asthma. Eur Respir J 2001; 16: Suppl. 31, 685

Member's Comments

No comment yet.

Related content which might interest you: Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003 Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids? Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003 Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004 Mometasone furoate is safe and effective for long-term use in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 148s Year: 2001 Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002 Mometasone furoate dry powder inhaler administered once-daily in the evening reduces overnight and early morning symptoms of mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003 Inhaled budesonide 800 μg once daily versus 400 μg twice daily in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001 Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014 Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003